Hong Kong Aims to be IPO Venue of Choice for Young China Life Science Companies

Innovent, Hua Medicine, Ascletis, Henlius, Shanghai Tasly, Ascentage, Grail -- each of these companies is a young, prominent China novel life science company. And each is pre-revenue, or at least pre-profit. Each one would like to stage an IPO to fund their late-stage clinical trials and commercialization. Up to now, no China-Hong Kong exchange would allow companies to IPO without a history of profitable operations. That's about to change. Later this year, Hong Kong is expected to begin IPOs for maturing (though not yet profitable) biopharmas. It's a big step forward, and each one of these companies is contemplating taking advantage of Hong Kong's offer. More details....

Share this with colleagues:

More From BioPortfolio on "Hong Kong Aims to be IPO Venue of Choice for Young China Life Science Companies"